Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28132597 | 0.81 | ACHE (0.44) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL1995788 | 0.80 | FAAH (0.53) | CYP1A2ALDH1A1KDM4EFAAH | |
| SCHEMBL421378 | 0.79 | BCL9 (0.53) | KMT2AMEN1CA2ALDH1A1KDM4E | |
| SCHEMBL29134204 | 0.78 | KMT2A (0.41) | KMT2AMEN1CA2ALDH1A1KDM4E | |
| SCHEMBL197021 | 0.75 | CYP3A4 (0.51) | KMT2AMEN1CA2ALDH1A1KDM4E | |
| SCHEMBL4374968 | 0.75 | CYP1A2 (0.54) | KMT2AMEN1CYP1A2CA2ALDH1A1 | |
| SCHEMBL4810160 | 0.75 | LMNA (0.62) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL305912 | 0.74 | CYP1A2 (0.70) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL20769806 | 0.74 | BCL9 (0.59) | KMT2AMEN1ALDH1A1KDM4EGLA | |
| SCHEMBL2089245 | 0.74 | CYP1A2 (0.70) | KMT2AMEN1CYP1A2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390343-B1 | NOVEL RETINOID DERIVATIVES AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2009-10-14 | — | — | EP | disclosed |
| US-7166744-B2 | Retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2007-01-23 | — | — | US | disclosed |
| EP-1390343-A4 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1390343-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | Chebigen Co., Ltd. (KR) | 2004-02-25 | — | — | EP | disclosed |
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
| WO-2002096857-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO., LTD. (KR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | RXRB, RARB, RXRA | KMT2A 3305/4885MEN1 2083/4885CYP1A2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.